<DOC>
	<DOCNO>NCT01766024</DOCNO>
	<brief_summary>This randomize double-blind crossover study pharmacokinetics , pharmacodynamics tolerability BCD-033 ( interferon beta-1a manufactured CJSC BIOCAD , Russia ) Rebif® ( Merck Serono S.p.A.. , Italy ) healthy volunteer . The purpose study demonstrate non-inferiority pharmacokinetics , pharmacodynamics tolerability parameter single subcutaneous injection . Each dtug administer volunteer dose 44 µg single subcutaneous injection interval least 14 day .</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics Study BCD-033 Compared Rebif® Healthy Volunteers</brief_title>
	<detailed_description>Each dtug ( BCD-033 Rebif ) administer volunteer dose 44 µg single subcutaneous injection interval least 14 day .</detailed_description>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Written inform consent ; Male gender ; Age 18 45 year inclusive ; Body mass index ( BMI ) ( 18,5 24,99 kg/m2 ) ; Healthy condition proven volunteer 's history , global assessment laboratory analysis result : Absence past medical history screen clinically significant dysfunction circulatory , respiratory , nervous , hematopoietic , endocrine digestive system , liver kidney ; Haematology biochemistry test , urinalysis thyroid hormone analysis result within normal limit accord standard study site . Screening laboratory analysis perform 14 day volunteer 's inclusion study ; Hemodynamic parameter within normal limit : systolic blood pressure 100 139 mmHg , diastolic blood pressure 60 90 mmHg , heart rate 50 90 bpm ; Absence history chronic infection ( tuberculosis ) chronic inflammation ; Absence HIV , hepatitis B C virus , syphilis ; Absence acute infection within 4 week inclusion study ; Absence psychiatric disorder condition interfere volunteer 's ability follow study protocol , include depression ; Wellbeing ( volunteer 's opinion ) within 30 day participation study ; Absence history systematic alcohol drug abuse ; Ability volunteer , investigator 's opinion , follow study protocol procedures requirement ; Willingness volunteer sexual partner childbearing potential use reliable contraception method start 2 week inclusion study 4 week receive last dose investigational product . This criterion applicable patient underwent surgical sterilization . Reliable contraceptive measure include one barrier method combination one follow method : spermicide , intrauterine device oral contraceptive use participant 's partner ; Consent avoid alcohol intake within 24 hour 8 day administration test reference drug ; Consent avoid grapefruit juice ( product contain grapefruit ) intake within 72 hour 8 day administration study reference drug . Previous use IFNβ1containing medication time inclusion ; History serious allergic reaction ( anaphylaxis multiple allergy ) ; Known allergy intolerance interferon component study reference drug ; Major surgery within 30 day screen ; Impossibility install venous catheter blood sampling ( e.g . skin disorder sit venipuncture ) ; Diseases condition interfere investigational drug pharmacokinetics ( e.g . chronic liver , kidney , blood , circulatory system , lung neuroendocrine disease , include diabetes mellitus others ) ; History epileptic seizure ; Regular oral parenteral use medication include overthecounter drug , vitamin nutritional additive within less 2 week inclusion study ; Intake medication , include overthecounter drug biologically active additive influence hemodynamics , liver function etc . ( barbiturate , omeprazole , cimetidine etc . ) within less 30 day inclusion study ; Intake medication influence immune status ( cytokine inductor , glucocorticoid etc . ) within less 30 day participation study ; Smoking 10 cigarette per day ; Subjects consume 10 unit alcohol per week history alcohol abuse evidence drug/chemical abuse ( one unit alcohol equal ½ l [ 500 ml ] beer , one glass [ 200 ml ] wine l shot glass [ 50 ml ] spirit ) ; Donation 450 ml blood plasma within 2 month inclusion study ; Participation clinical study within less 1 month inclusion study simultaneous participation another clinical study ; Previous participation study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>interferon beta-1a</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>volunteer</keyword>
</DOC>